Treatment Clinical Trials for Endometrial Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for endometrial cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 96

  • Short Course Radiation Therapy after Surgery for the Treatment of Endometrial Cancer in Patients Receiving Chemotherapy, DeCRESCEndo Trial

    This trial investigates how well short course radiation therapy works after surgery in treating patients with endometrial cancer who are receiving or have received chemotherapy. Short course (hypofractionated) radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects compared to standard radiation therapy.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Study of AMG 650 in Adult Participants With Advanced Solid Tumors

    To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D).
    Location: 2 locations

  • NIAGEN for the Alleviation of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

    The phase II trial studies how well NIAGEN works in reducing peripheral neuropathy caused by chemotherapy in cancer survivors who have completed their cancer treatment. NIAGEN is a nutritional supplement and type of vitamin B3. NIAGEN may help alleviate peripheral neuropathy that persists in patients who have completed cancer treatment.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Olaparib and Entinostat in Treating Patients with Recurrent, Platinum-Refractory or Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

    This phase I / II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Tumor samples from patients will be tested for a specific change in their genetic materials (DNA) called homologous recombination deficiency (HRD). Patients who lack this genetic change will be eligible to participate in this study. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Mirvetuximab Soravtansine and Pembrolizumab for the Treatment of Microsatellite Stable Advanced or Recurrent Endometrial Cancer

    This phase II trial studies how well mirvetuximab soravtansine and pembrolizumab work in treating patients with microsatellite stable endometrial cancer that has spread to other places in the body (advanced) or has come back (recurrent). Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells. Mirvetuximab soravtansine is an antibody-drug conjugate, a type of agent attaches a chemotherapy drug to a molecule that binds to a protein on the outside of cancer cells. The protein targeted by mirvetuximab soravtansine is called folate receptor-alpha (FRalpha). FRalpha is expressed on the surface of certain cancers, including endometrial cancer cells. Mirvetuximab soravtansine may to kill cancer cells by delivering chemotherapy drugs to cells that have high levels of FRalpha and may also activate immune cells and improving the response to immunotherapies like pembrolizumab. Giving mirvetuximab soravtansine and pembrolizumab may shrink or prevent the growth of endometrial cancers compared to giving pembrolizumab alone.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
    Location: Hackensack University Medical Center, Hackensack, New Jersey

  • Nivolumab with or without Ipilimumab in Treating Patients with Recurrent or High Grade Gynecologic Cancer with Metastatic Peritoneal Carcinomatosis

    This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating patients with female reproductive cancer that has come back (recurrent) or is high grade and has spread extensively throughout the peritoneal cavity (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • ONC201 in Recurrent / Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

    Background: The new drug ONC201 have been shown to kill breast cancer and endometrial cancer cells in the laboratory. The exact mechanism of action is not completely clear yet, but the ONC201 destroys the mitochondria inside the cells. Blocking mitochondrial activity may kill tumor cells, which would shrink tumors. Researchers want to see if ONC201 helps shrink tumors of certain breast or endometrial cancers and if that effect is maintained. Objective: To see if ONC201 shrinks tumors with a lasting effect. Eligibility: Adults ages 18 and older who have metastatic breast cancer (hormone-positive or triple-negative) or metastatic endometrial cancers. Design: Participants will be screened with: Medical history Physical exam Heart, blood, and urine tests CT and bone scans Review of medical report and tumor sample Participants will have a tumor biopsy before starting treatment and after 5 weeks taking the study drug. A scan or ultrasound may be used to guide the biopsy. Patients will receive local anesthetic and a needle will remove a small piece of tumor. The study will be done in 28-day cycles. Every day 1 of each cycle participants will repeat most screening tests, will be seen by the physician and receive a supply of the study drug. Participants will take the study drug by mouth once every 7 days. They will keep a diary of when they take the drug and any side effects. During cycle 1, participants will get weekly calls to discuss their health and symptoms. Images will be repeated every 2 cycles to evaluate reponse to the treatment. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Stereotactic Body Radiation Therapy in Treating Patients with Recurrent Primary Ovarian or Uterine Cancer

    This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with ovarian or uterine cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
    Location: University of Colorado Hospital, Aurora, Colorado

  • PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss

    This phase I / II trial studies the side effects and best dose of PI3K-beta inhibitor GSK2636771 when given together with pembrolizumab and to see how well they work in treating patients with stage III-IV cancer and PTEN loss. PI3K-beta inhibitor GSK2636771 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving PI3K-beta inhibitor GSK2636771 and pembrolizumab may work better in treating patients with metastatic cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Selective Surgical Staging in Predicting Lymph Node Removal in Patients with Endometrial Cancer Undergoing Surgery

    This clinical trial evaluates selective surgical staging in the treatment of women with early stage endometrial cancer (EC). The standard treatment for women with EC includes the surgical removal of the uterus (hysterectomy), both fallopian tubes and ovaries (bilateral salpingo-oophorectomy), and sometimes the lymph nodes (lymph node sampling). Even though this is a common malignancy, gynecologic oncologists still disagree on the best treatment for early EC. Some surgeons choose not to remove any lymph nodes, some perform lymph node sampling, and others remove all related lymph nodes (lymphadenectomy). Since lymph node removal is associated with adverse events, it should only be performed when necessary. By performing a systematic examination of the uterus after its removal (intraoperative consultation, IOC), doctors can better determine whether or not lymphadenectomy should be performed. Using this treatment strategy, the extent of the surgery is tailored to match the risk that the woman’s lymph nodes will be involved by cancer. After completion of the IOC, women with high-risk cancers are treated with lymphadenectomy while women with low-risk cancers are not.
    Location: University of Kentucky / Markey Cancer Center, Lexington, Kentucky

  • Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

    Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head and neck squamous cell carcinoma (HNSCC) as well as a variety of other tumor types. This study is designed primarily to assess the safety and tolerability of COTI-2 monotherapy or combination therapy in patients with advanced and recurrent malignancies to establish a recommended Phase 2 dose (RP2D) for future studies. Patients are currently being recruited for Part 3 of the study. Critical Outcome Technologies Inc. has been renamed to Cotinga Pharmaceuticals.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

    A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
    Location: 5 locations

  • Sacituzumab Govitecan for the Treatment of Persistent or Recurrent Endometrial Cancer

    This phase II trial studies how well sacituzumab govitecan works in treating patients with endometrial cancer that remains despite treatment (persistent) or has come back (recurrent). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan. Sacituzumab attaches to TROP2 positive cancer cells in a targeted way and delivers govitecan to kill them.
    Location: Yale University, New Haven, Connecticut

  • Study of DS-7300a in Participants With Advanced Solid Malignant Tumors

    This study is in one single group of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: - Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of DS-7300a. - Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of DS-7300a. This study is expected to last approximately 3.5 years from the time the first participant is enrolled to the time the last participant is off the study. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: - they withdraw - their disease gets worse - they experience unacceptable side effects.
    Location: M D Anderson Cancer Center, Houston, Texas

  • HIIT before Surgery in Improving Outcomes in Patients with Endometrial Cancer

    This trial studies how well HIIT before surgery works in improving outcomes in patients with endometrial cancer. HIIT is an exercise strategy where short intense exercise periods are interspersed with recovery periods. Endometrial cancer is an obesity driven disease. Obesity creates a tumor enhancing environment. HIIT before surgery may improve outcomes in patients with endometrial cancer by slowing development of the tumor.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic Cancers

    This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.
    Location: M D Anderson Cancer Center, Houston, Texas

  • TSR-042 and Radiation for the Treatment of Stage I-II Endometrial Cancer

    This phase I trial studies the side effects of TSR-042 and radiation in treating stage I-II endometrial cancer. Immunotherapy with TSR-042, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving TSR-042 in combination with radiation therapy may work better in treating patients with endometrial cancer compared to radiation therapy alone.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • GEN1046 Safety Trial in Patients With Malignant Solid Tumors

    The purpose of the trial is to evaluate the safety of GEN1046 in patients with malignant solid tumors
    Location: 6 locations

  • Pembrolizumab and Chemotherapy in Treating Patients with High-Grade Obesity-Driven Endometrial Cancer

    This early phase I trial studies how well pembrolizumab works before surgery and in combination with standard chemotherapy after surgery in treating patients with high-grade obesity-driven endometrial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab before surgery and in combination with standard chemotherapy after surgery may work better in patients with endometrial cancer.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Megestrol Acetate with or without Pterostilbene in Treating Patients with Endometrial Cancer Undergoing Hysterectomy

    This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pterostilbene is an antioxidant found in blueberries or grapes, and it has been shown to be effective in killing tumor cells and reducing cancer burden. It is not yet known whether giving megestrol acetate with or without pterostilbene may work better in treating patients with endometrial cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

    This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of AB928 in combination with AB122 (an anti-PD-1 antibody) in participants with advanced malignancies.
    Location: 2 locations

  • Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back. Niraparib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Early Palliative Care in Improving Recovery and Quality of Life in Patients with Cancer Undergoing Abdominal Surgery, the SCOPE Trial

    This trial studies early palliative care in improving recovery and quality of life in patients with cancer undergoing abdominal surgery. Frequently people diagnosed with cancer experience physical and emotional symptoms during the course of their disease. Introduction to a team of clinicians that specialize in the lessening of many of these distressing symptoms may improve overall care. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management (i.e. shortness of breath, fatigue, anxiety, etc.) and to assist patients and their families in coping with the emotional, social, and spiritual issues associated with a cancer diagnosis. This study is being done to see if receiving palliative care earlier is more useful compared to receiving palliative care late in the course of illness.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee